MSF's new report outlines the issues surrounding access to DR-TB drugs, including - the limited number of quality sources, including few quality assured producers and limited sources of the active pharmaceutical ingredient; limited affordability, due to drug price variables and prices that have increased ; and the need to produce drugs suitable for children and people with HIV.
DRTB Drugs Under The Microscope-
pdf — 314.7 KB